These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 17205524)

  • 21. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells.
    Hsu JC; Zhang J; Dev A; Wing A; Bjeldanes LF; Firestone GL
    Carcinogenesis; 2005 Nov; 26(11):1896-904. PubMed ID: 15958518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells.
    Alexander B; Fishman AI; Green D; Choudhury MS; Konno S
    Urol Oncol; 2013 Jan; 31(1):104-9. PubMed ID: 21795077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY; Ly LH; Peehl DM; Feldman D
    Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
    Eder IE; Culig Z; Ramoner R; Thurnher M; Putz T; Nessler-Menardi C; Tiefenthaler M; Bartsch G; Klocker H
    Cancer Gene Ther; 2000 Jul; 7(7):997-1007. PubMed ID: 10917202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
    Rae JM; Johnson MD; Cordero KE; Scheys JO; Larios JM; Gottardis MM; Pienta KJ; Lippman ME
    Prostate; 2006 Jun; 66(8):886-94. PubMed ID: 16496412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The organoselenium compound 1,4-phenylenebis(methylene)selenocyanate inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorgenesis and enhances glutathione-related antioxidant levels in A/J mouse lung.
    Richie JP; Kleinman W; Desai DH; Das A; Amin SG; Pinto JT; El-Bayoumy K
    Chem Biol Interact; 2006 Jun; 161(2):93-103. PubMed ID: 16620795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling.
    Dong Y; Lee SO; Zhang H; Marshall J; Gao AC; Ip C
    Cancer Res; 2004 Jan; 64(1):19-22. PubMed ID: 14729601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
    Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
    Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elucidation of molecular targets of mammary cancer chemoprevention in the rat by organoselenium compounds using cDNA microarray.
    El-Bayoumy K; Narayanan BA; Desai DH; Narayanan NK; Pittman B; Amin SG; Schwartz J; Nixon DW
    Carcinogenesis; 2003 Sep; 24(9):1505-14. PubMed ID: 12844480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells.
    Sung SY; Kubo H; Shigemura K; Arnold RS; Logani S; Wang R; Konaka H; Nakagawa M; Mousses S; Amin M; Anderson C; Johnstone P; Petros JA; Marshall FF; Zhau HE; Chung LW
    Cancer Res; 2006 Oct; 66(19):9519-26. PubMed ID: 17018608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro gene expression changes of androgen receptor coactivators after hormone deprivation in an androgen-dependent prostate cancer cell line.
    Chang HC; Chen SC; Chen J; Hsieh JT
    J Formos Med Assoc; 2005 Sep; 104(9):652-8. PubMed ID: 16276440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterisation of steroid receptor expression in the human prostate carcinoma cell line 22RV1 and quantification of androgen effects on mRNA regulation of prostate-specific genes.
    Hartel A; Didier A; Ulbrich SE; Wierer M; Meyer HH
    J Steroid Biochem Mol Biol; 2004 Oct; 92(3):187-97. PubMed ID: 15555912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD; Gleave ME
    Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
    Nesslinger NJ; Shi XB; deVere White RW
    Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
    Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
    Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular targets of the chemopreventive agent 1,4-phenylenebis (methylene)-selenocyanate in human non-small cell lung cancer.
    El-Bayoumy K; Das A; Narayanan B; Narayanan N; Fiala ES; Desai D; Rao CV; Amin S; Sinha R
    Carcinogenesis; 2006 Jul; 27(7):1369-76. PubMed ID: 16399772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism.
    Hsieh TC; Wu JM
    Anticancer Res; 2000; 20(1A):225-8. PubMed ID: 10769659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
    Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
    Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.